David A. Siegel Vertex Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 122,000 shares of VRTX stock, worth $57.2 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

122,000

Previous 87,500 39.43%

Holding current value

$57.2 Million

Previous $35.6 Million 43.24%

% of portfolio

0.12%

Previous 0.08%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $14.1 Million - $15.4 Million	34,500 Added 39.43%	122,000 $51 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $19.2 Million - $23 Million	-55,900 Reduced 38.98%	87,500 $35.6 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $24 Million - $25.7 Million	-71,000 Reduced 33.12%	143,400 $49.9 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $48.4 Million - $54.2 Million	154,000 Added 254.97%	214,400 $75.4 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $12.1 Million - $13.8 Million	42,600 Added 239.33%	60,400 $19 Million

Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $1.49 Million - $1.67 Million	-5,200 Reduced 22.61%	17,800 $5.14 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $465,511 - $519,400	-1,700 Reduced 6.88%	23,000 $6.66 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $1.62 Million - $2.02 Million	6,900 Added 38.76%	24,700 $6.96 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $1.22 Million - $1.44 Million	5,500 Added 44.72%	17,800 $4.65 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $136 Million - $172 Million	-770,400 Reduced 98.43%	12,300 $2.7 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $142 Million - $159 Million	781,700 Added 78170.0%	782,700 $142 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $187,490 - $221,100	1,000 New	1,000 $202,000
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $54.4 Million - $63.4 Million	-262,837 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $107 Million - $142 Million	-514,800 Reduced 66.2%	262,837 $62.1 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $112 Million - $133 Million	-438,275 Reduced 36.04%	777,637 $212 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $25.7 Million - $33.7 Million	113,900 Added 10.34%	1,215,912 $353 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $20.5 Million - $25.5 Million	-102,700 Reduced 8.52%	1,102,012 $262 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $50.2 Million - $67.4 Million	301,100 Added 33.32%	1,204,712 $264 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $5.34 Million - $6.01 Million	-32,100 Reduced 3.43%	903,612 $153 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $11.1 Million - $12.9 Million	-67,700 Reduced 6.75%	935,712 $172 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $42.3 Million - $50.3 Million	258,400 Added 34.68%	1,003,412 $185 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $33.3 Million - $42.1 Million	219,000 Added 41.63%	745,012 $123 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $32.3 Million - $37.1 Million	192,600 Added 57.77%	526,012 $101 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $69.9 Million - $81.5 Million	-479,800 Reduced 59.0%	333,412 $56.7 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $62.8 Million - $73.4 Million	-414,200 Reduced 33.75%	813,212 $133 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $50.5 Million - $57.3 Million	368,162 Added 42.85%	1,227,412 $184 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $127 Million - $139 Million	859,250	859,250 $131 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account